TSHA vs TTRX

Taysha Gene Therapies, Inc. vs Turn Therapeutics Inc. — Valuation Comparison 2026

TSHA

Biotechnology
Taysha Gene Therapies, Inc.
Quality
6.0
out of 10
Value Trap
18
SAFE
Price
$5.92
Last close
Models
9/13
Active
VS

TTRX

Biotechnology
Turn Therapeutics Inc.
Quality
4.2
out of 10
Value Trap
Price
$5.31
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType TSHA Fair ValueTSHA Upside TTRX Fair ValueTTRX Upside
Bayesian DCF Intrinsic $2.02 -65.8% $1.52 -71.5%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $•••.•• ••.•% $•••.•• ••.•%
Dynamic NAV Asset-Based $1.05 -82.3% $0.13 -97.5%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
RCMH-DCF Intrinsic $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for TSHA vs TTRX — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

TSHA vs TTRX — Which Stock Is More Undervalued?

TSHA scores higher with a 6.0/10 quality rating vs TTRX's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Taysha Gene Therapies, Inc. (TSHA) and Turn Therapeutics Inc. (TTRX) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

TSHA currently trades at $5.92 with a QOC of 6.0/10, while TTRX trades at $5.31 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).